368 related articles for article (PubMed ID: 21508668)
1. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
2. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
3. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
5. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
Puca R; Nardinocchi L; Bossi G; Sacchi A; Rechavi G; Givol D; D'Orazi G
Exp Cell Res; 2009 Jan; 315(1):67-75. PubMed ID: 18996371
[TBL] [Abstract][Full Text] [Related]
6. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
7. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.
Liu K; Ling S; Lin WC
Mol Cell Biol; 2011 Nov; 31(22):4464-81. PubMed ID: 21930790
[TBL] [Abstract][Full Text] [Related]
8. Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein.
Punganuru SR; Madala HR; Arutla V; Srivenugopal KS
Carcinogenesis; 2018 Dec; 39(11):1399-1410. PubMed ID: 30010803
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.
Kim EJ; Park JS; Um SJ
J Biol Chem; 2002 Aug; 277(35):32020-8. PubMed ID: 11925430
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.
Kravchenko JE; Ilyinskaya GV; Komarov PG; Agapova LS; Kochetkov DV; Strom E; Frolova EI; Kovriga I; Gudkov AV; Feinstein E; Chumakov PM
Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6302-7. PubMed ID: 18424558
[TBL] [Abstract][Full Text] [Related]
12. Rescue of mutant p53 transcription function by ellipticine.
Peng Y; Li C; Chen L; Sebti S; Chen J
Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
[TBL] [Abstract][Full Text] [Related]
13. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
15. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC.
Knoll S; Fürst K; Thomas S; Villanueva Baselga S; Stoll A; Schaefer S; Pützer BM
Cell Cycle; 2011 Oct; 10(20):3554-65. PubMed ID: 22030623
[TBL] [Abstract][Full Text] [Related]
16. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
17. The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells.
Garufi A; Ubertini V; Mancini F; D'Orazi V; Baldari S; Moretti F; Bossi G; D'Orazi G
J Exp Clin Cancer Res; 2015 Aug; 34(1):87. PubMed ID: 26297485
[TBL] [Abstract][Full Text] [Related]
18. Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes.
Xie B; Nagalingam A; Kuppusamy P; Muniraj N; Langford P; Győrffy B; Saxena NK; Sharma D
Sci Rep; 2017 Jan; 7():40070. PubMed ID: 28071670
[TBL] [Abstract][Full Text] [Related]
19. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
He Y; Fan SZ; Jiang YG
Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
[TBL] [Abstract][Full Text] [Related]
20. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
